|
Collaboration Agreement (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 1 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2012
|
Sep. 30, 2013
Collaborative Arrangement [Member]
|
Dec. 31, 2009
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2013
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2013
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2012
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2013
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Minimum [Member]
|
Sep. 30, 2013
Collaborative Arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Maximum [Member]
|
Dec. 31, 2009
Collaborative Arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
|
Dec. 31, 2009
Collaborative Arrangement [Member]
University of British Columbia [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||
| Collaboration Agreement aggregate amount | $ 50,000,000 | |||||||||||||
| Maximum amount receivable | 370,000,000 | |||||||||||||
| Equity investment | 53,777,000 | 10,000,000 | 10,000,000 | |||||||||||
| Royalties at percentage rates ranging | Mid-teens to mid-twenties on net sales | |||||||||||||
| Share premium | 20.00% | |||||||||||||
| Common shares, purchase price | $ 37.38 | |||||||||||||
| Common shares purchased | 267,531 | |||||||||||||
| Average premium period | 30 days | |||||||||||||
| Research and development | 18,004,000 | 12,895,000 | 42,122,000 | 24,303,000 | 10,000,000 | 300,000 | ||||||||
| Percentage of milestone payments required to be paid to third party | 31.00% | |||||||||||||
| Percentage of net sales required to be paid as royalty to third party | 4.88% | 8.00% | ||||||||||||
| Required contribution for direct and indirect development costs | 30,000,000 | |||||||||||||
| Direct and indirect costs incurred | 30,000,000 | |||||||||||||
| Required period of notice for termination of Collaboration Agreement | 3 months | 6 months | ||||||||||||
| Expiration of royalties | 10 years | |||||||||||||
| Period of authorization change | 90 days | |||||||||||||
| Amounts receivable | 9,922,000 | 9,922,000 | 714,000 | 9,900,000 | ||||||||||
| Revenue | $ 9,862,000 | $ 6,570,000 | $ 21,278,000 | $ 10,315,000 | $ 9,900,000 | $ 21,300,000 | ||||||||